D
X4 Pharmaceuticals, Inc. XFOR
$0.21 -$0.018-7.90%
Recommendation
Sell
Prev Close
$0.228
Volume
1,587,854
Avg Vol (90D)
3,441,196
Market Cap
$39.60M
Dividend & Yield
--
52-Week Range
$0.2067 - $1.60
P/E (TTM)
--
EPS (TTM)
-$0.1877
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Analysts' Top Healthcare Picks: X4 Pharmaceuticals (XFOR), TriSalus Life Sciences (TLSI)
3/27/2025 - TipRanks Financial Blog
Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views
3/27/2025 - Benzinga
X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Misses Estimates By $0.03 EPS
3/26/2025 - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: X4 Pharmaceuticals (XFOR), Sanara MedTech (SMTI)
3/26/2025 - TipRanks Financial Blog
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ...
3/26/2025 - GuruFocus
Q4 2024 X4 Pharmaceuticals Inc Earnings Call Transcript
3/26/2025 - GuruFocus
X4 Pharmaceuticals Reports 2024 Financial Results
3/26/2025 - TipRanks Financial Blog
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
3/25/2025 - SeekingAlpha
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
3/25/2025 - Seeking Alpha: Transcripts
X4 Pharmaceuticals price target lowered to $3 from $4 at Stifel
3/25/2025 - TipRanks Financial Blog
X4 Pharmaceuticals price target lowered by $1 at Stifel, here's why
3/25/2025 - The Fly
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings: Revenue Surpasses Estimates at $1. ...
3/25/2025 - GuruFocus
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...
3/25/2025 - GuruFocus
X4 Pharmaceuticals GAAP EPS of -$0.20 misses by $0.03, revenue of $1.43M beats by $0.37M
3/25/2025 - SeekingAlpha.com: All News
X4 Pharmaceuticals reports Q4 EPS (20c) vs. (10c) last year
3/25/2025 - The Fly
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/25/2025 - Globe Newswire
X4 Pharmaceuticals Q4 2024 Earnings Preview
3/24/2025 - SeekingAlpha.com: All News
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To Look For
3/24/2025 - GuruFocus
X4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on Tuesday
3/18/2025 - MarketBeat
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a ...
3/11/2025 - GuruFocus
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
3/11/2025 - Globe Newswire
X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) Critical Analysis
3/3/2025 - Ticker Report
X4 Pharmaceuticals partners with taiba rare for distribution of XOLREMDI drug
2/19/2025 - SeekingAlpha.com: All News
X4 Pharmaceuticals partners with taiba rare for distribution of XOLREMDI drug
2/19/2025 - Seeking Alpha - Healthcare
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI (mavorixafor) in WHIM Syndrome in Select Middle East Countries
2/19/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$2.56M
EBITDA (TTM)
-$140.61M
EBIT (TTM)
-$141.40M
Net Income (TTM)
-$37.45M
Balance Sheet
Total Assets (Q)
$146.45M
Total Debt (Q)
$78.09M
Total Liabilities (Q)
$124.30M
Book Value Per Share (Q)
$0.1296
Cash Flow
Cash from Operations (TTM)
-$130.90M
Cash from Investing (TTM)
$66.99M
Cash from Financing (TTM)
$20.29M
Net Change in Cash (TTM)
-$43.77M
Filings
Filing Date
Wednesday, March 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.11
7-Day Total Return
-19.04%
30-Day Total Return
-55.64%
60-Day Total Return
-71.62%
90-Day Total Return
-38.31%
Year to Date Total Return
-72.07%
1-Year Total Return
-85.71%
2-Year Total Return
-76.80%
3-Year Total Return
-89.01%
5-Year Total Return
-97.59%
52-week Low
Apr 02, 2025 - $0.2067
52-week High
Apr 03, 2024 - $1.60
Valuation
Market Cap
$39.60M - Nano Cap
Enterprise Value
$15.62M
Price/Sales (TTM)
18.10
Price/Book (Q)
1.76
Dividends and Shares
Shares Outstanding
202.93M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.x4pharma.com
Phone Number
857 529 8300
Address
61 North Beacon Street
Boston, MA 02134
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system... more
NASDAQ 04/03/2025 4:00PM Eastern Quotes delayed
Weiss Ratings